Enfusion, Inc.

Equities

ENFN

US2928121043

Software

Market Closed - Nyse 04:00:02 2024-04-23 pm EDT 5-day change 1st Jan Change
9.35 USD +1.30% Intraday chart for Enfusion, Inc. +0.86% -3.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Enfusion Shares Slip After Short-Seller Spruce Point Warns of 'Financial Restatement Risk' MT
BofA Securities Adjusts Price Target on Enfusion to $9 From $8, Maintains Underperform Rating MT
Enfusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sector Update: Tech Stocks Advance Pre-Bell Tuesday MT
Enfusion, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Enfusion, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Enfusion Q4 Earnings Flat, Revenue Gains; Provides 2024 Revenue Outlook MT
North American Morning Briefing : Inflation Data -2- DJ
North American Morning Briefing : Fed's Preferred -2- DJ
Sector Update: Tech Stocks Drop Late Afternoon MT
Sector Update: Tech MT
Enfusion Shares Decline Following Goldman Sachs Downgrade MT
Goldman Sachs Downgrades Enfusion to Sell From Neutral, Trims Price Target to $8 From $9 MT
North American Morning Briefing : Big Tech Weighs -2- DJ
JPMorgan Downgrades Enfusion to Underweight From Neutral, Cut Price Target to $9 From $11 MT
Enfusion, Inc. Elevates Valeria Gutowski to Chief Accounting Officer CI
Enfusion Insider Sold Shares Worth $9,860,000, According to a Recent SEC Filing MT
Enfusion Names Neal Pawar COO MT
Enfusion, Inc. Appoints Neal Pawar as Chief Operating Officer, Effective November 27, 2023 CI
UBS Adjusts Enfusion Price Target to $9.50 From $9, Maintains Neutral Rating MT
Enfusion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
UBS Initiates Coverage on Enfusion With Neutral Rating, $9 Price Target MT
Enfusion, Inc. Reaffirms Earnings Guidance for the Year 2023 CI
Transcript : Enfusion, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Enfusion, Inc. announced that it has received $7.65 million in funding CI
Chart Enfusion, Inc.
More charts
Enfusion, Inc. provides software-as-a-service (SaaS) platform for investment managers. The Company, through its software, analytics, and middle/back-office managed services, creates enterprise-wide cultures of real-time, data-driven intelligence and collaboration. The Company's cloud-native, end-to-end solution gives its clients the ability to access and analyze investment information in real time, perform complex calculations and interact with markets electronically adding up to better, more informed investment decisions and actions. Its solution is highly configurable to different work streams, client segments and asset classes. The Company's solution includes portfolio management system, order and execution management system, accounting/general ledger system, Enfusion Analytics System and technology-powered, managed services. Its solution is utilized by a variety of users, including portfolio managers, traders, compliance officers, operational support staff and executive management.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
9.23 USD
Average target price
9.821 USD
Spread / Average Target
+6.41%
Consensus
  1. Stock Market
  2. Equities
  3. ENFN Stock
  4. News Enfusion, Inc.
  5. Earnings Flash (ENFN) ENFUSION Reports Q2 Revenue $36.5M, vs. Street Est of $35.6M